An Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants

Das, Ankit; Ranadive, Niraja; Kinra, Manas; Nampoothiri, Madhavan; Arora, Devinder; Mudgal, Jayesh

doi:10.2174/1570159x18666200221113842

Cited by 40 publications

(18 citation statements)

References 95 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic treatment with chemotherapeutic agents causes a deficit in central BDNF levels, affecting neuronal functions (NG et al 2015). Approaches to resume the BDNF levels in the brain by certain drugs such as antidepressants (Fluoxetine) have been discussed and provide their scope of implication as a therapeutic strategy for CICI (Das et al 2020).…”

Section: Impaired Neurogenesismentioning

confidence: 99%

Animal models of chemotherapy-induced cognitive decline in preclinical drug development

et al. 2021

Self Cite

View full text Add to dashboard Cite

Rationale Chemotherapy-induced cognitive impairment (CICI), chemobrain, and chemofog are the common terms for mental dysfunction in a cancer patient/survivor under the influence of chemotherapeutics. CICI is manifested as short/long term memory problems and delayed mental processing, which interferes with a person’s day-to-day activities. Understanding CICI mechanisms help in developing therapeutic interventions that may alleviate the disease condition. Animal models facilitate critical evaluation to elucidate the underlying mechanisms and form an integral part of verifying different treatment hypotheses and strategies. Objectives A methodical evaluation of scientific literature is required to understand cognitive changes associated with the use of chemotherapeutic agents in different preclinical studies. This review mainly emphasizes animal models developed with various chemotherapeutic agents individually and in combination, with their proposed mechanisms contributing to the cognitive dysfunction. This review also points toward the analysis of chemobrain in healthy animals to understand the mechanism of interventions in absence of tumor and in tumor-bearing animals to mimic human cancer conditions to screen potential drug candidates against chemobrain. Results Substantial memory deficit as a result of commonly used chemotherapeutic agents was evidenced in healthy and tumor-bearing animals. Spatial and episodic cognitive impairments, alterations in neurotrophins, oxidative and inflammatory markers, and changes in long-term potentiation were commonly observed changes in different animal models irrespective of the chemotherapeutic agent. Conclusion Dyscognition exists as one of the serious side effects of cancer chemotherapy. Due to differing mechanisms of chemotherapeutic agents with differing tendencies to alter behavioral and biochemical parameters, chemotherapy may present a significant risk in resulting memory impairments in healthy as well as tumor-bearing animals.

show abstract

Section: Impaired Neurogenesismentioning

confidence: 99%

Animal models of chemotherapy-induced cognitive decline in preclinical drug development

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…And, a recent double-blind randomized controlled trial showed that compared with minimum acupuncture stimulation, electroacupuncture trigeminal nerve stimulation plus body acupuncture showed advantages in improving the quality of life of cancer patients and reducing working memory impairment [119]. At the same time, antidepressants such as fluoxetine may alleviate CRCI by balancing cytokines [120]. Aspirin is known to have anti-inflammatory properties.…”

Section: Othersmentioning

confidence: 99%

Pathogenesis, Assessments, and Management of Chemotherapy-Related Cognitive Impairment (CRCI): An Updated Literature Review

Mao

Dong

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

There are various cancer treatments at present, and chemotherapy is one of the main methods. Chemotherapy-related cognitive impairment (CRCI), as one of the side effects of chemotherapy, has gradually attracted the attention of more and more researchers. CRCI has been verified by subjective reports and objective neuropsychological tests so far. But oncologists’ understanding of it and its treatments are still incomplete. In this review, we mainly give a comprehensive overview of the mechanism of CRCI, then describe a variety of evaluation methods, and finally summarize the treatment approaches under current medical conditions and compare it with an excellent article published in 2015 with the aim of providing directions for future research and better understanding of CRCI for clinicians.

show abstract

“…It is known that docetaxel compromises the structural integrity of the cerebral cortex and peripheral neurons [ 51 ]. Both doxorubicin and cyclophosphamide induced behavioral impairments, although only the last was associated with inflammation caused by microglia [ 52 ]. Variable levels of cytokine concentrations and cognitive impairment severity are associated with distinct chemotherapy regimens and doses.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Accuracy of Machine-Learning Models on Predicting Chemo-Brain in Breast Cancer Survivors Previously Treated with Chemotherapy: A Meta-Analysis

Turcu-Știolică

Bogdan

Dumitrescu

et al. 2022

IJERPH

View full text Add to dashboard Cite

We performed a meta-analysis of chemo-brain diagnostic, pooling sensitivities, and specificities in order to assess the accuracy of a machine-learning (ML) algorithm in breast cancer survivors previously treated with chemotherapy. We searched PubMed, Web of Science, and Scopus for eligible articles before 30 September 2022. We identified three eligible studies from which we extracted seven ML algorithms. For our data, the χ2 tests demonstrated the homogeneity of the sensitivity’s models (χ2 = 7.6987, df = 6, p-value = 0.261) and the specificities of the ML models (χ2 = 3.0151, df = 6, p-value = 0.807). The pooled area under the curve (AUC) for the overall ML models in this study was 0.914 (95%CI: 0.891–0.939) and partial AUC (restricted to observed false positive rates and normalized) was 0.844 (95%CI: 0.80–0.889). Additionally, the pooled sensitivity and pooled specificity values were 0.81 (95% CI: 0.75–0.86) and 0.82 (95% CI: 0.76–0.86), respectively. From all included ML models, support vector machine demonstrated the best test performance. ML models represent a promising, reliable modality for chemo-brain prediction in breast cancer survivors previously treated with chemotherapy, demonstrating high accuracy.

show abstract

An Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants

Cited by 40 publications

References 95 publications

Animal models of chemotherapy-induced cognitive decline in preclinical drug development

Animal models of chemotherapy-induced cognitive decline in preclinical drug development

Pathogenesis, Assessments, and Management of Chemotherapy-Related Cognitive Impairment (CRCI): An Updated Literature Review

Diagnostic Accuracy of Machine-Learning Models on Predicting Chemo-Brain in Breast Cancer Survivors Previously Treated with Chemotherapy: A Meta-Analysis

Contact Info

Product

Resources

About